Valclan

Quick links to important sections

Valclan

Selected form

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Valclan

Property Description
Active Ingredients Amoxicillin, Clavulanic Acid
Form Tablet, Suspension, Injection
Pharmacological Class Penicillin-class Antibiotic / beta-Lactam Agent
General Purpose Combats bacterial infections, including resistant strains
Origin Semisynthetic Derivative

What Type of Medicine is Valclan (Co-amoxiclav)?

Valclan is a prescription pharmaceutical preparation classified as a broad-spectrum antibacterial agent belonging to the penicillin class of antibiotics. This medicine is defined as a fixed-dose combination product, a formulation clinically recognized for its ability to address antibiotic resistance effectively. Being a semisynthetic derivative, it represents a modified and improved generation of early penicillin compounds. The International Nonproprietary Name (INN) for this formulation is Co-amoxiclav, which is manufactured globally under various trade names.

Composition: Amoxicillin, Clavulanic Acid, and Available Forms

The composition of Valclan is the synergistic pairing of Amoxicillin and Clavulanic Acid (Co-amoxiclav). Amoxicillin functions as the primary beta-lactam antibacterial agent, while Clavulanic Acid acts as a molecular shield, classified as a beta-lactamase inhibitor. This combination is commonly supplied in several dosage forms, including oral tablets, powder for oral suspension (often formulated for pediatric patient groups), and preparations for intravenous administration. This range of forms allows flexibility in treatment based on the severity and site of the bacterial infection.

How Valclan Works to Overcome Resistance

The general purpose of Valclan is to provide reliable treatment by combating bacterial infections, which is often necessary for common conditions like respiratory or skin infections. While Amoxicillin performs bacterial cell wall disruption, Clavulanic Acid works via enzyme protection, neutralizing the beta-lactamase enzymes that otherwise inactivate Amoxicillin. This integrated action expands the antibiotic's spectrum, making the fixed combination a powerful defense against a wider scope of bacterial pathogens.

Regulatory References

  1. Amoxicillin and Clavulanate Potassium FDA Label

What side effects are possible with Valclan?

Valclan (amoxicillin and clavulanate) is generally well-tolerated, but like all medications, it can cause side effects. Most side effects are mild and temporary. Taking this medication at the start of a meal can help reduce stomach upset.

Common Side Effects

These side effects occur in more than 1 in 100 people:

  • Gastrointestinal issues: Diarrhea (most common), nausea, and vomiting. Diarrhea may persist after the course of treatment is finished.
  • Skin reactions: Skin rash, hives, and itching.
  • Fungal infections: Vaginal yeast infections (vaginitis) and oral thrush.

Serious Side Effects and Safety Warnings

Seek immediate medical attention if you experience any of the following signs of a serious reaction:

  • Severe allergic reaction (Anaphylaxis): Swelling of the face, lips, tongue, or throat, difficulty breathing, or a widespread, severe skin rash.
  • Liver problems: Symptoms include yellowing of the skin or eyes (jaundice), dark urine, pale stools, unexplained fatigue, and persistent nausea or vomiting.
  • Severe skin reactions: Blistering, peeling, or loosening of the skin, including in the mouth or genital area, often accompanied by flu-like symptoms (e.g., fever, sore throat).
  • Severe persistent diarrhea: Watery or bloody diarrhea, with or without stomach cramps and fever, which may be a sign of a serious intestinal condition (Clostridioides difficile-associated diarrhea).

Safety Information

Valclan is contraindicated if you have a history of a severe allergic reaction to penicillin-class antibiotics or have previously developed liver problems or jaundice while taking amoxicillin/clavulanate. Use caution in patients with kidney disease or liver impairment, as dose adjustments or close monitoring may be necessary. This medication may also reduce the effectiveness of oral contraceptives, so alternative birth control methods should be considered.

Overdose and Emergency Response

Overdose with Valclan (Co-amoxiclav) is officially documented to present primarily with severe gastrointestinal manifestations, including vomiting, diarrhea, and abdominal pain. A specific physiological finding noted in regulatory summaries is crystalluria, where the presence of crystals in the urine may lead to decreased urinary output. In cases involving high systemic exposure, particularly in individuals with pre-existing impaired renal function, neurological effects such as convulsions or seizures are documented as a potential presentation. Overdose is also associated with the risk of hepatic dysfunction, including cholestatic jaundice, with regulatory notes indicating higher incidence in males and the elderly.

Emergency medical attention is officially mandated when serious signs occur. Patients must seek immediate medical attention for the onset of a seizure, difficulty breathing, or any indication of a severe hypersensitivity reaction. Official guidance instructs contacting a Poison Control Helpline immediately upon suspicion of overdose. Management is described as symptomatic and supportive treatment because no specific antidote is available. For severe cases, regulatory documents note that both the amoxicillin and clavulanic acid components can be removed from circulation using hemodialysis. Close monitoring of renal function and fluid balance is required following a significant overdose.

Therapeutic Uses of Valclan

What Valclan Treats: Main Uses and Benefits

Valclan (Co-amoxiclav) is a therapeutic agent commonly used to manage active bacterial infections in several body systems, and may assist in managing symptoms related to the infection. This medication is commonly applied in situations where patients experience infections of the ears, lungs, sinus, skin, and urinary tract. It is generally relevant in conditions characterized by periods of heightened symptoms or where the infection is considered difficult to manage.

The medication is applied across domains that include acute bacterial infections of the respiratory tract (like sinusitis and community-acquired pneumonia), ear and throat (like otitis media), skin and soft tissues (like cellulitis), and complicated systemic infections (like pyelonephritis). It is often used in contexts involving heightened systemic burden or when symptoms are associated with challenging infection patterns.

“It is commonly used to help address groups of symptoms that may become intense or disruptive, such as fever, localized pain, and functional discomfort, which supports general well-being during symptomatic phases.”


Key Therapeutic Support

This medicine is considered relevant in clinical settings that involve acute or unstable symptom patterns, such as managing infections resulting from animal or human bites or acute exacerbations of chronic lung conditions. By supporting the reduction of the bacterial load, Valclan assists in easing distressing systemic manifestations, contributing to easing the overall symptom load and helps maintain a sense of stability when symptoms are more noticeable.


Quick Fact: Symptom Support This medication may be part of symptomatic management for inflammatory or irritative states caused by infection, and is commonly used to help with symptoms that interfere with daily functioning.

Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

Who Can and Cannot Use Valclan? (Co-amoxiclav)

Official regulatory documents define strict criteria for eligibility based on patient history, comorbidities, age, and organ function. Valclan is contraindicated and must not be used in individuals with a history of a serious hypersensitivity reaction (e.g., anaphylaxis) to any penicillin or other beta-lactam antibiotic (such as cephalosporins). It is also strictly prohibited for patients with a previous history of cholestatic jaundice or hepatic dysfunction associated with prior Co-amoxiclav treatment.


Eligibility Classification Population Status (Regulatory Basis)
Absolute Non-Eligibility History of serious penicillin/beta-lactam allergy, or prior Co-amoxiclav-associated hepatic dysfunction.
Restricted Use Patients with severe renal impairment (CrCl < 30 mL/min) are restricted from using high-dose tablets (e.g., 875 mg/125 mg) and require dose adjustment. Use in hepatic impairment requires caution and monitoring.
Not Recommended Patients with infectious mononucleosis must avoid this medicine due to the high risk of developing a generalized skin rash.
Age Thresholds Use is established in children 3 months of age and older. Safety and effectiveness are not established for infants younger than 3 months. Older adults generally require no dose adjustment based on age alone, but renal function monitoring is recommended.
Physiological Status Use during pregnancy (Pregnancy Category B) is generally allowed only if clearly needed, and it is not recommended in women with preterm, premature rupture of fetal membranes (pPROM).

These guidelines establish mandatory exclusions and specific conditional requirements that must be followed to ensure the medicine is only administered to eligible populations according to regulatory standards.

What should I know about interactions with other medicines?

Valclan Interactions with other medicines and products

This section describes official interaction information documented in government regulatory sources.

Interaction Scope

Category Entities and Official Outcomes
Specific Interacting Medicines Probenecid, Oral Anticoagulants, Allopurinol, Methotrexate, Combined Oral Contraceptives.
Mechanistic Basis Pharmacokinetic (PK) interference with renal tubular secretion; Pharmacodynamic (PD) effects on coagulation and hormonal stability.
Timing Rules No mandatory administration separation rules are documented.
Food Interaction Absorption of the Clavulanic Acid component is enhanced when Valclan is administered with food.
Population Notes Risk of interaction-related hepatotoxicity and altered INR effects may be heightened in elderly patients or those with hepatic impairment.

Interaction-Related Restrictions The use of Valclan is officially contraindicated in patients with infectious mononucleosis due to the high risk of developing a skin rash. It is also restricted for patients with a documented history of cholestatic jaundice or liver dysfunction specifically associated with prior Amoxicillin/Clavulanic Acid use.

Official Interaction Statements

  • Co-administration with Probenecid is a PK interaction that increases and prolongs the plasma concentration of Amoxicillin.
  • Concurrent use with Oral Anticoagulants is associated with an increased prolongation of prothrombin time (INR).
  • Valclan may reduce the efficacy of combined oral contraceptives.

Connection to the overall interaction profile Regulatory documents define this product's interaction structure based on mandatory restrictions and required monitoring for concurrent therapy. The constraints address both pharmacokinetic interference with elimination pathways and pharmacodynamic consequences related to clotting factors and hormonal stability.

Mechanism of Action

Inhibiting the Structural Integrity of Bacterial Cells

The primary antibacterial mechanism relies on Amoxicillin directly targeting Penicillin-Binding Proteins ( PBPs)—enzymes essential for constructing the rigid bacterial cell wall. By irreversibly binding to and inhibiting these PBPs, the drug blocks the final step of peptidoglycan cross-linking, causing the cell wall to become structurally defective. This failure to maintain integrity results in rapid cell lysis due to overwhelming internal osmotic pressure, leading to a bactericidal physiological effect.

Overcoming Resistance via Enzyme Protection

The secondary mechanism is executed by Clavulanic Acid, which functions solely to protect Amoxicillin. It acts as a suicide inhibitor against certain beta-Lactamase enzymes, the bacterial defense mechanism used to chemically degrade Amoxicillin. Clavulanic Acid irreversibly inactivates the beta-Lactamase, thereby preserving the Amoxicillin's functional concentration. This restores Amoxicillin's ability to engage the PBP target, allowing the cell-destruction mechanism to occur against resistant bacterial strains.

Dosage and Administration Information

How to Use Valclan (Amoxicillin and Clavulanate Potassium) — Official Administration Guidelines

This section outlines the mandatory procedural instructions for using Valclan, based on prescribing information.


Administration Scope

Feature Instruction
Route of Administration Oral (tablet, chewable tablet, or reconstituted suspension). Intravenous (IV) is available for specific settings and formulations.
Dosing Schedule Highly variable, determined by formulation (IR/XR), strength, and patient factors. Standard adult dosing examples include 875 mg/125 mg every 12 hours or 500 mg/125 mg every 8 hours. Pediatric dosing is weight-based (mg/kg/day).
Timing in Relation to Meals Oral formulations must be taken at the start of a meal to enhance the absorption of the clavulanate component and reduce the risk of gastrointestinal discomfort.
Duration of Course Treatment should not be extended beyond 14 days without review by a healthcare provider.

Procedural Requirements and Restrictions

  • Tablet Integrity: Extended-Release (XR) tablets must be swallowed whole and not crushed, broken, or chewed to preserve the controlled release mechanism. Immediate-release tablets should also be swallowed whole.
  • Suspension Preparation: The dry powder for oral suspension requires reconstitution with a specific, measured volume of water. The bottle must be shaken well immediately before each dose to ensure accurate dosing.
  • Dose Equivalence: Certain tablet strengths are not substitutable for others (e.g., two 250 mg/125 mg tablets are not equivalent to one 500 mg/125 mg tablet) due to differing ratios of the active ingredients.
  • Population-Specific Rules: Patients with significant renal impairment (Creatinine Clearance <30 mL/min) require mandatory dose adjustments and must not use the 875 mg tablet or the Extended-Release formulation. Pediatric dosing is strictly weight-based.

Recent Clinical Evidence

Research evidence / Overview of studies for Valclan

Evidence for Use in Acute Bacterial Rhinosinusitis and Otitis Media

Research examining the use of Valclan for infections affecting the sinuses and middle ear was studied for through Randomized Controlled Trials (RCTs) and systematic summaries of clinical evidence. These studies were designed to monitor outcomes related to clinical status and changes in symptoms over time during the short-term treatment period. The research explored the application of this medicine in both adults and pediatric patients. The trials reported the percentage of participants who met the criteria for a predefined measurement of clinical status. Long-term durability of these reported short-term outcomes is not extensively detailed.

Evidence for Use in Community-Acquired Pneumonia and Chronic Lung Exacerbations

Research for lower respiratory tract conditions involves large multicenter RCTs and observational cohort studies, which was studied for in contexts such as Community-Acquired Pneumonia (CAP). These studies monitored primary outcomes related to clinical status (such as fitness for hospital discharge) and 30-day mortality rates in patient groups, including hospitalized adults and older adults. Data show patterns related to hospital readmission frequencies. Long-term functional recovery is not fully established in the primary clinical trials, and data for supporting non-inferiority against narrow-spectrum alternatives remain an area of ongoing research.

Evidence in Specific Patient Populations

Research has explored the use of Valclan in pediatric patients (children) for conditions such as acute otitis media, with studies monitoring clinical status and changes in symptoms in these specific age groups. Furthermore, research examined the use of Valclan in studies focusing on older adults (geriatric populations). However, data for certain groups remain insufficient, such as those in very specific comorbidity-defined groups, where data is largely observational or limited to small sample sizes.

Key Studies & References

  1. Management of acute otitis media in children: an umbrella review of clinical practice guidelines and systematic reviews
  2. Community-Acquired Pneumonia (CAP) - Medscape Reference
  3. Recommendations | Cellulitis and erysipelas: antimicrobial prescribing | Guidance - NICE

Frequently Asked Questions (FAQ)

Common questions about Valclan (FAQ)


Q: What is the main reason Valclan is prescribed?

Official documents state that the medication is indicated for treating infections caused by susceptible bacteria. These infections include those of the lower respiratory tract, acute bacterial otitis media (middle ear infection), sinusitis, and skin and urinary tract structures.


Q: Are there any common foods or drinks to avoid while using Valclan?

Regulatory documents do not list specific common foods or drinks that must be avoided while using this medication. However, official administration guidelines recommend taking Valclan at the start of a meal. This instruction is given because taking the medicine with food is known to help reduce stomach upset, according to official administration guidelines.


Q: Why is the dosage of Valclan sometimes different for different people?

The required dosage is determined by several specific patient and infection factors, as outlined in official prescribing information. These factors include the type and site of the infection, the patient's age and weight, and the presence of severe renal (kidney) impairment, which may necessitate a dose adjustment.


Q: Is Valclan safe to use for people with existing liver problems?

Official prescribing information states that the medicine must not be used by patients who have a history of liver problems (cholestatic jaundice or hepatic dysfunction) specifically related to prior use of Amoxicillin/Clavulanate. For individuals with existing hepatic impairment, official guidelines recommend monitoring liver function tests at regular intervals during treatment.


Q: Can taking Valclan cause problems with kidney function?

Official reports from the penicillin class of antibiotics, to which Valclan belongs, include rare reports of interstitial nephritis (kidney inflammation) and the formation of crystals in the urine (crystalluria). The prescribing information notes that these events have been observed in rare cases.


Q: Can pregnant or breastfeeding individuals use Valclan?

The official classification indicates that the medicine should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. For breastfeeding, one of the active components (Amoxicillin) is known to be excreted in small amounts in human milk, and rare reports of rash, diarrhea, and restlessness in the infant have been noted.


Q: What is the risk of experiencing a serious allergic reaction to Valclan?

Serious and occasionally fatal hypersensitivity, or anaphylactic, reactions have been reported with this medication. Official documents state these reactions are known to occur in individuals with a history of hypersensitivity to penicillin or other beta-lactam antibiotics.


Q: What does the research say about Valclan's long-term effects?

Research studies supporting the medicine's use primarily monitor outcomes over a short-term treatment period, which is typically up to 14 days. Official documents state that long-term functional recovery is not fully established in the primary clinical trials.


Q: What is the most important piece of safety information about Valclan?

The official prescribing information highlights two major warnings that are critical to patient safety. These concern the risk of severe hypersensitivity (allergic) reactions, which require immediate medical attention, and the potential risk of severe liver dysfunction or cholestatic jaundice.


Q: Does taking Valclan require routine blood tests?

Routine blood testing is not required for every patient using the medication. However, monitoring of liver function tests is recommended for patients who have existing hepatic impairment (liver problems). Official guidelines recommend blood monitoring (such as prothrombin time/INR) for individuals who are also taking oral anticoagulant medications.


Q: How is Valclan’s effectiveness generally described in clinical trials?

Official product information indicates that the drug is approved for infections caused by bacteria demonstrated to be susceptible to the medicine. Clinical trials are designed to monitor outcomes related to clinical recovery and measurable changes in symptoms, and the results supported the drug’s intended use.


Q: What is the difference between Valclan’s brand name and its chemical name?

Valclan is the brand name used for the product, while the International Nonproprietary Name (INN) for the drug combination is Co-amoxiclav. The active ingredients are Amoxicillin and Clavulanate Potassium.


Q: Is Valclan available in different strengths?

Yes, according to official labeling, the medication is manufactured in various dosage forms and strengths. These include different formulations of oral tablets, chewable tablets, and powders for oral suspension.


Q: What is the general safety profile of Valclan?

Official prescribing information indicates that the combination product is generally well-tolerated. The most frequently reported adverse effects are mild and transient, such as diarrhea, nausea, vomiting, and skin rashes. However, serious side effects, including severe allergic reactions and liver problems, can occur rarely.


Q: What does the FDA say about the clinical evidence for Valclan?

The FDA approved the medication for treating specific bacterial infections based on a review of clinical studies that established its safety and effectiveness for those uses. Official product information documents the clinical evidence that supported its approval and defines the appropriate use and limitations.


Q: Is Valclan considered a first-line treatment for its approved condition?

Clinical practice guidelines indicate that Amoxicillin/Clavulanate is recommended as a first-line oral treatment for some conditions, such as acute bacterial otitis media and certain lower respiratory tract infections. This recommendation is often made when there is a clinical suspicion of infection caused by bacteria that produce beta-lactamase enzymes.


Q: Is it possible for Valclan to affect sleep patterns?

Official reports from the Central Nervous System (CNS) adverse reaction category include rare reports of insomnia (difficulty sleeping) and reversible hyperactivity.


Q: What does 'contraindication' mean in relation to Valclan?

The term contraindication, as used in regulatory documents, refers to a condition or factor in a patient that requires the drug to be strictly withheld. This is because the risk of a serious harmful outcome, such as a severe allergic reaction or liver problems, is judged to outweigh any potential therapeutic benefit.


Q: Does Valclan have a 'Black Box Warning' in its official labeling?

The drug does not carry a Black Box Warning in its official FDA labeling, which is the most stringent type of warning. The prescribing information does, however, list serious warnings and precautions related to hypersensitivity reactions and liver dysfunction.


Q: Is Valclan a controlled substance, and what does that mean?

According to official labeling, Valclan is not classified as a controlled substance in the U.S., and its official DEA Schedule is listed as 'None'. A controlled substance is a drug whose use and distribution is tightly regulated by the government due to its potential for abuse or dependence.


Q: How long does Valclan stay in the body after the last use?

The drug’s components are known to be rapidly excreted from the body. Official data shows that most of the medication is eliminated through the urine within the first six hours after administration.


Q: Can Valclan make you feel dizzy or lightheaded?

Yes, official product information indicates that dizziness has been reported rarely as a Central Nervous System adverse reaction.


Q: Is it normal to feel a bit tired when first starting Valclan?

Official documents report that unusually weak or tired feelings (fatigue) have been noted rarely as an adverse reaction. Patients should be aware that fatigue is also listed as a potential symptom of more serious adverse reactions like liver problems.


Q: Does Valclan affect your ability to drive or operate machinery?

Official reports indicate that rare adverse reactions such as dizziness, agitation, and confusion have been reported as Central Nervous System effects. These effects may impair a person's ability to drive or safely operate machinery.


Q: What specific ingredients are in Valclan tablets besides the main drug?

The tablets contain inactive ingredients (excipients) in addition to the active components (Amoxicillin and Clavulanate Potassium). These inactive ingredients are listed in official documents and include substances such as magnesium stearate, microcrystalline cellulose, and titanium dioxide.


Q: Are there any known interactions between Valclan and herbal supplements?

Official patient information advises individuals to inform their healthcare provider about all prescription and nonprescription medicines, vitamins, nutritional supplements, and herbal products they are taking or plan to take. This instruction is given due to the potential for these products to interact with the medication.


Q: Can Valclan cause changes in mood or behavior?

Official adverse reaction reports indicate that agitation, anxiety, behavioral changes, and confusion have been reported rarely as Central Nervous System side effects.


Q: Are any interactions listed for Valclan and common vitamins or minerals?

Official patient information instructs individuals to inform their healthcare provider about all vitamins and nutritional supplements they are taking. This is recommended because these products may interact with the medicine.


Q: Does Valclan interact with alcohol, and what is the official caution?

Official documents do not state a known direct interaction between the drug and alcohol. However, official cautions indicate that drinking alcohol may increase the risk of certain side effects, such as nausea, vomiting, and liver problems.


Q: What is the typical time frame for side effects to appear after starting Valclan?

The time frame for side effects varies according to official clinical data summaries. Skin rashes usually begin around the fifth day of treatment, while antibiotic-associated diarrhea may occur during treatment or up to two months after stopping.


Q: Is it necessary to inform other doctors that I am using Valclan?

Official patient information strongly advises telling all healthcare providers about every prescription and nonprescription medicine currently being used. This is an important step to prevent potential drug interactions and ensure safe prescribing.


Q: Does Valclan have a known potential for causing headaches?

According to summaries of adverse reaction data, headache is listed as a commonly reported side effect of the medication.

How should Valclan be stored and disposed of?

Storage and Disposal Requirements

Official regulatory guidelines for Valclan (Co-amoxiclav) storage differ based on the form. Tablets and the dry powder for suspension must be stored at or below 25^circC and protected from moisture, kept securely in the original container. Once the oral suspension is mixed (reconstituted), it requires mandatory refrigeration, stored between 2^circC and 8^circC.

Product Form Storage Temperature Stability Constraint
Tablets / Dry Powder Below 25^circC Protect from moisture
Reconstituted Suspension 2^circC to 8^circC (Refrigerated) Must be discarded after 10 days; do not freeze

All forms of Valclan must be stored out of the sight and reach of children. Unused or expired medication must be disposed of according to local regulatory requirements and should not be thrown away via wastewater or household drains.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Valclan found in:

A-Z Index: